Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL vs LEXAPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.
Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder (off-label),Vasomotor symptoms of menopause (off-label)
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder (off-label),Panic disorder (off-label),Post-traumatic stress disorder (off-label),Premenstrual dysphoric disorder (off-label)
20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.
10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.
Mean terminal half-life 21 hours (range 3–65 hours); steady-state achieved within 7–14 days; nonlinear kinetics with dose increase leading to disproportionate increases in half-life due to saturable hepatic metabolism (CYP2D6).
27-32 hours (mean ~30 h); steady state reached in ~1 week; linear kinetics at therapeutic doses.
Extensively metabolized primarily via cytochrome P450 (CYP) 2D6, with minor contributions from CYP3A4 and CYP1A2. The parent drug accounts for <1% of excretion. Metabolites include paroxetine catechol and paroxetine glucuronide conjugates.
Primarily hepatic via CYP3A4 and CYP2C19; active metabolite S-desmethylcitalopram.
Renal: 64% (2% unchanged, 62% as metabolites); Fecal: 36% via bile; urinary excretion of unchanged paroxetine <2%.
Primarily renal (approx. 80% as metabolites, 8% as unchanged drug); biliary/fecal elimination accounts for ~15%.
93–95% bound to plasma proteins (primarily alpha-1-acid glycoprotein and albumin).
Approximately 56% bound to plasma proteins (mainly albumin and alpha-1-acid glycoprotein).
11 L/kg (range 3–28 L/kg); extensive tissue distribution with concentrations in CNS exceeding plasma.
12-26 L/kg (mean ~20 L/kg); extensive extravascular distribution consistent with high lipophilicity.
Oral: 50% (range 30–60%; limited by first-pass metabolism); food does not significantly affect extent of absorption, but may slightly delay Tmax.
Oral: approximately 80% (range 60-90%) after a single dose; food does not significantly affect absorption.
For GFR <30 m L/min: initial dose 10 mg/day; maximum 40 mg/day. Hemodialysis: no supplemental dose needed.
No dosage adjustment for mild to moderate impairment. Not recommended for severe impairment (Cr Cl <20 m L/min).
Child-Pugh Class A or B: initial dose 10 mg/day; maximum 40 mg/day. Child-Pugh Class C: not recommended.
For Child-Pugh class A or B: 10 mg orally once daily. Use caution in severe impairment (Child-Pugh class C); limited data.
Not approved for patients <18 years; off-label use for OCD in children 7–17 years: starting 10 mg/day, titrate by 10 mg/week to target 20–50 mg/day (max 60 mg/day).
Adolescents 12-17 years: 10 mg orally once daily. Children <12 years: not approved.
Initial dose 10 mg/day; maximum 40 mg/day. Increase in 10 mg increments at intervals of at least 1 week.
Initial 5 mg orally once daily; maximum 10 mg once daily.
Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Paroxetine is not approved for use in pediatric patients.
Increased risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
Suicidality risk in children, adolescents, and young adults,Serotonin syndrome (potentially life-threatening) when co-administered with other serotonergic drugs,MAOI interaction (at least 14-day washout period),Discontinuation syndrome (dizziness, sensory disturbances, anxiety, etc.) upon abrupt withdrawal,Increased risk of bleeding (especially with NSAIDs, aspirin, or anticoagulants),Activation of mania/hypomania in patients with bipolar disorder,Seizure risk (use caution in patients with seizure disorders),Angle-closure glaucoma (pupillary dilation risk),Hyponatremia (elderly, volume-depleted patients),Bone fracture risk (epidemiological studies),Fetal harm (epidemiological data suggest increased risk of cardiovascular malformations, particularly ventricular outflow obstructions, with first-trimester exposure; consider risk/benefit)
Suicidality risk in young adults,Serotonin syndrome,QT prolongation,Hyponatremia,Bleeding risk,Activation of mania/hypomania,Seizure risk,Abrupt discontinuation syndrome
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concurrent use of pimozide or thioridazine (QT prolongation and pharmacokinetic interaction),Hypersensitivity to paroxetine or any component of the formulation
Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Concomitant use of pimozide,Hypersensitivity to escitalopram or citalopram,QT prolongation or congenital long QT syndrome (for citalopram, caution for escitalopram)
No significant food interactions; may be taken with or without food. Grapefruit juice does not interact. Avoid excessive alcohol.
Grapefruit juice may increase escitalopram exposure; avoid concurrent use. Alcohol can potentiate central nervous system depression; limit or avoid alcohol consumption. No significant food interactions; may be taken with or without food.
First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn (PPHN) risk increased ~2-fold; overall absolute risk <.5% for major malformations. Second/third trimester: Risk of preterm delivery, low birth weight, neonatal serotonin discontinuation syndrome (irritability, feeding difficulties, respiratory distress, tremors).
First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk of approximately 1-2%. Second/third trimester: Late pregnancy exposure may increase risk for persistent pulmonary hypertension of the newborn (PPHN) and serotonin syndrome in the neonate. Third trimester use may lead to neonatal adaptation syndrome including irritability, respiratory distress, and feeding difficulties.
Paroxetine is excreted into breast milk with an estimated infant dose of ~1% of maternal weight-adjusted dose; M/P ratio is approximately 0.56. Cases of irritability, poor feeding, and drowsiness in breastfed infants have been reported; cautious use recommended, with monitoring for adverse effects.
Escitalopram is excreted into human breast milk with a milk-to-plasma ratio (M/P) of approximately 2.0. Infant serum levels are typically low, but some cases of adverse effects such as irritability, feeding problems, and sleep disturbance have been reported. The American Academy of Pediatrics considers escitalopram compatible with breastfeeding, but caution is advised, especially in premature or compromised infants.
Increased plasma volume and hepatic metabolism in pregnancy may reduce paroxetine levels; consider upward dose titration (20-40% increase) in second and third trimesters based on clinical response; monitor for worsening depression; taper gradually postpartum to avoid discontinuation syndrome.
Pharmacokinetic changes during pregnancy (increased volume of distribution, increased clearance) may require dose adjustments. Escitalopram clearance increases by approximately 50% in the third trimester. Dose increases may be needed to maintain efficacy, with gradual reduction postpartum to pre-pregnancy dose over 2-4 weeks. Therapeutic drug monitoring of escitalopram and its metabolite S-DCT is recommended if available, targeting trough levels of 15-80 ng/m L.
Paroxetine has a short half-life and is associated with significant withdrawal syndrome upon abrupt discontinuation; taper slowly. It is the most anticholinergic SSRI, causing more constipation, dry mouth, and sedation. Use with caution in elderly due to hyponatremia risk. It is also a weak inhibitor of CYP2D6, potentially increasing levels of co-administered drugs like tamoxifen or metoprolol.
LEXAPRO (escitalopram) is the S-enantiomer of citalopram with less cytochrome P450 inhibition, minimizing drug interactions compared to racemic citalopram. QT prolongation risk is dose-dependent; maximum dose is 20 mg/day. Avoid co-administration with MAOIs and other serotonergic drugs due to serotonin syndrome risk. Abrupt discontinuation may cause withdrawal symptoms; taper over 1-2 weeks. Onset of therapeutic effect is 2-4 weeks. Use with caution in hepatic impairment (max dose 10 mg) and elderly patients.
Take exactly as prescribed; do not stop suddenly or change dose without consulting doctor.,May cause drowsiness; avoid driving until you know how you react.,Avoid alcohol while taking this medication.,Notify doctor if you experience serotonin syndrome symptoms: agitation, hallucinations, fast heartbeat, fever, muscle stiffness, nausea, diarrhea.,Inform all healthcare providers you are taking paroxetine, especially before surgery or any new medication.,Do not take with MAOIs or within 14 days of stopping MAOIs.
Take LEXAPRO once daily, either in the morning or evening, consistently with or without food.,Do not stop taking this medication suddenly; consult your doctor for a gradual dose reduction to avoid withdrawal symptoms.,Inform your doctor of all medications you are taking, especially MAOIs (e.g., linezolid, methylene blue), other antidepressants, and blood thinners.,Avoid alcohol and grapefruit juice as they may increase side effects.,Contact your doctor immediately if you experience suicidal thoughts, serotonin syndrome symptoms (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness), or prolonged QT interval symptoms (e.g., palpitations, fainting).,It may take several weeks to feel the full benefit; continue taking as prescribed.,Monitor for worsening depression or anxiety, especially during the first few months of treatment.,If pregnant or planning to become pregnant, discuss risks with your doctor (may cause neonatal complications).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL vs LEXAPRO, answered by our medical review team.
PAXIL is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft, leading to increased serotonin levels.. LEXAPRO is a SSRI Antidepressant that works by Selective serotonin reuptake inhibitor (SSRI); inhibits serotonin reuptake at the presynaptic neuron, potentiating serotonergic activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL and LEXAPRO depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL is: 20 mg orally once daily, typically in the morning; may be increased in 10 mg/day increments at intervals of at least 1 week to a maximum of 50 mg/day.. The standard adult dose of LEXAPRO is: 10 mg orally once daily; may increase to 20 mg once daily after at least 1 week.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL and LEXAPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL is classified as Category C. First trimester: Risk of congenital cardiac defects (primarily ventricular and atrial septal defects) with relative risk ~1.5-1.7; persistent pulmonary hypertension of the newborn . LEXAPRO is classified as Category C. First trimester: Epidemiologic studies have shown a small increased risk of congenital cardiac defects (primarily ventricular septal defects) with exposure, with an absolute risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.